# Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

> **NCT01333046** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 36 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Disease

## Interventions

- **BIOLOGICAL:** Antigen-Escalation Stage
- **BIOLOGICAL:** Dose-Escalation Stage
- **BIOLOGICAL:** azacytidine and multiTAA T cells Stage
- **BIOLOGICAL:** Pediatric multiTAA T cells Stage

## Key facts

- **NCT ID:** NCT01333046
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-01
- **Primary completion:** 2021-09-27
- **Final completion:** 2027-09-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333046, "Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01333046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*